eXoZymes (NASDAQ:EXOZ) Stock Price Up 1% – What’s Next?

eXoZymes Inc. (NASDAQ:EXOZ) rose 1% during mid-day trading on Tuesday . The stock traded as high as $7.80 and last traded at $7.42. Approximately 2,530 shares changed hands during trading, a decline of 60% from the average daily volume of 6,279 shares. The stock had previously closed at $7.35.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of eXoZymes in a report on Friday, May 29th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, eXoZymes has an average rating of “Sell”.

eXoZymes Trading Up 1.0%

The business’s fifty day simple moving average is $9.78 and its 200 day simple moving average is $10.20. The company has a current ratio of 1.32, a quick ratio of 1.32 and a debt-to-equity ratio of 0.03. The stock has a market cap of $62.92 million, a P/E ratio of -6.51 and a beta of 2.65.

eXoZymes (NASDAQ:EXOZ) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.28) EPS for the quarter.

About eXoZymes

eXoZymes, Inc develops, manufactures and supplies a range of enzymes and reagents designed for molecular biology research and diagnostic applications. The company’s enzyme engineering platform underpins a portfolio of products aimed at supporting nucleic acid purification, amplification and analysis workflows.

Key offerings from eXoZymes include magnetic bead–based nucleic acid extraction kits, DNA polymerases, reverse transcriptases, proteases and custom enzyme services. In addition, the company provides molecular diagnostic test kits designed for pathogen detection, leveraging scalable production processes and quality systems aligned with regulatory standards.

eXoZymes serves academic research institutions, biotechnology and pharmaceutical companies, and clinical diagnostic laboratories worldwide.